Accumulating evidence implicates an integral role for inflammation in all aspects of coronary syndromes, from the pathogenesis of atherosclerosis to plaque rupture and myocardial cell death. In each of these steps, infiltration of cardiovascular tissue with inflammatory cells is evident and is orchestrated by a number of cytokines and cell adhesion molecules. Furthermore, soluble markers of cellular inflammation are present in different stages of ischaemic heart disease and these markers of inflammation may be used to predict subsequent cardiovascular events [1] . Nonetheless, the role of different inflammatory mediators in various stages of acute coronary syndromes is not fully defined and the prognostic information provided by these biomarkers remains controversial. Recent studies, including the innovative study by O'Malley et al. [2] in this issue, have tried to more specifically determine the predictive significance of many of these inflammatory makers in acute coronary syndromes. They observed that plasma levels of C-reactive protein (CRP), interleukin-6 (IL-6) and soluble intracellular adhesion molecule-1 (ICAM-1) were all elevated early in acute coronary syndromes, with 71% of the levels drawn within 10 h of the index chest pain. Thus, this provides one of the most detailed studies with regard to the timing of alterations in inflammatory markers. These biomarkers were also strongly correlated with smoking, whereas soluble vascular cell adhesion molecule-1 (VACM-1) and platelet P-selectin were not and were not increased in their study population. Both the IL-6 and the CRP levels normalized during the 3-month follow-up period, while ICAM-1 remained elevated in the acute coronary syndrome patients. This study suggests that smoking may mediate some of its proatherogenic effects through inflammation and ICAM-1 and supports the premise that inflammation is a fundamental component of the development of acute coronary syndromes.
The study by O'Malley and colleagues does have a few limitations. First, the study was done only in patients under the age of 65. This resulted in a population with less co-morbidity and allowed them to more closely determine the interaction of these markers with cardiac risk factors, in the setting of acute coronary syndromes. However, this makes their data less applicable to the general cardiac patient, as typically these patients are older and have other medical conditions. To what extent the changes in serum markers noted in this study can be expanded to a more general population is undefined.
The persistent elevation in ICAM-1 at 3 months, in contrast with a decline in IL-6 and CRP levels may be a reflection of this particular marker in the development of, or in the initiation of, the acute coronary
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syndrome, as the authors suggest. There are, however, other explanations. Normalization of IL-6 and CRP, 3 months after the cardiac event may, in part, be related to changes in medical therapies and riskfactor modification such as a cessation of smoking, and these were not evaluated in this study. Alternatively, ICAM-1 may simply be a more sensitive index of milder degrees of a chronic inflammatory state that persists after the acute coronary syndrome has resolved.
Multiple prior studies have evaluated inflammatory markers to both predict future cardiac events and to help delineate non-cardiac chest pain from acute coronary syndromes. Of the inflammatory markers, CRP has been one of the best established and is regarded as a potential emerging cardiac risk factor (Table 1) . CRP is an acute phase reactant synthesized in the liver after induction by cytokines released from injured tissues. The exact role of CRP in vivo is still controversial, but its utility as a biomarker is becoming more established. In an acute myocardial infarction, the rise in CRP is associated with the extent of myocardial cell death, whereas elevated CRP is not seen in patients with stable angina or those undergoing routine angiography [3] . Furthermore, in an acute myocardial infarction these levels are more prognostic than creatine kinase in predicting myocardial rupture, aneurysmal formation, congestive heart failure and 1-year mortality [4] . In patients not having an acute myocardial infarction, CRP correlates with the extent of coronary atherosclerosis and predicts future cardiovascular events [5] [6] [7] [8] [9] . Although some of this relationship is mediated through an association with classic cardiovascular risk factors such as cholesterol and chronic infections, CRP remains an important independent predictor of ischaemic events [6] . In a study by Tataru and colleagues, the extent and severity of atherosclerosis correlated with CRP in patients with a prior myocardial infarction [9] . CRP is also an independent marker of future cardiovascular events in healthy women, with a relative rise of 4·4 for the highest quartile of CRP levels compared with the lowest and added incremental value of lipid levels in determining cardiovascular risk [10] . Furthermore, in a nested case-control study from the Physicians' Health study in healthy men, the CRP level was a prognostic marker of future myocardial infarctions and strokes [7] . In this group the greatest benefits from aspirin use was found in those with the highest CRP levels. This in turn raises another unresolved, but intriguing issue. The efficacy of aspirin in both the primary and secondary prevention of coronary artery disease is somewhat surprising, given that it is a relatively weak antiplatelet agent. Perhaps the wheel has turned a full circle in that some of the benefits of aspirin are due to its antiinflammatory actions that were first appreciated 100 years ago.
IL-6 is another cytokine mediator that is part of the acute phase response and is associated with increases in CRP. In an acute myocardial infarction, IL-6 is elevated within 4-9 h from the onset of ischaemia and is more sensitive that creatine kinase in differentiating unstable angina from a myocardial infarction [11] [12] [13] . Some studies have demonstrated that the rise in serum levels of IL-6 correlates with the size of the myocardial infarction [14] , although this has not been a consistent observation in other studies [11] . In a nested case-control study of apparently healthy men from the Physicians' Health study, IL-6 was significantly higher in those who subsequently developed a myocardial infarction compared with those who did not [15] . IL-6 was again associated with CRP, but remained an independent predictor of future events. Thus, IL-6 levels can help to predict both future myocardial infarctions in overtly healthy individuals and acute myocardial infarctions in patients with chest pain.
On the surface of endothelial cells, ICAM-1 mediates inflammation by interactions with integrins to facilitate the adhesion of activated leukocytes and transmigration through the vascular endothelium. Moreover, ICAM-1 functions as a costimulatory molecule and activates T-cells. In addition to the important role of ICAM-1 in mediating myocardial cell injury, ICAM-1 is secreted into the serum. Although it is not known if soluble ICAM-1 has a physiological function, it has been evaluated as a marker for acute and chronic coronary disease. In patients with an acute myocardial infarction, soluble ICAM-1 increases within the first 8 h and remains elevated for at least 5 days [16, 17] . When percutaneous transluminal coronary angioplasty was used for treatment of an acute myocardial infarction, soluble ICAM-1 was not only elevated early but remained elevated in patients who developed early restenosis [18] . In children, soluble ICAM-1 is positively correlated with apoB B/A-I and significantly correlated with risk factors for atherosclerosis [19] . In a nested case-control study from the Physicians' Health Study in healthy men, soluble ICAM-1 predicted future myocardial infarctions [1] . Soluble ICAM-1 was associated with subsequent cardiac events in patients with peripheral vascular disease, although this factor was no longer significant after multivariate analysis [20] . In summary, inflammatory markers, including cellular adhesion molecules such as ICAM-1, [3]
Acute MI CRP predicts myocardial rupture, aneurysmal formation, congestive heart failure, and 1-year mortality.
[4]
Prior MI CRP is a marker for the extent and severity of atherosclerosis in patients who have had an MI.
[9]
Healthy men CRP predicts future myocardial infarctions and strokes. This risk is independent of smoking and lipids and the greatest benefit in aspirin use is demonstrated in patients with the highest CRP.
[7]
Interleukin-6
Acute MI IL-6 is significantly elevated in patients with an acute MI compared with those with unstable angina. IL-6 is more sensitive than the initial creatine kinase in detecting a MI.
[12]
Acute MI IL-6 is increased for up to 4 weeks after an acute MI and is higher than controls.
[11]
Acute MI Rises in IL-6 follow rises in IL-1 and peak at 4-9 hours after a MI.
[13]
Healthy men Increased IL-6 is found in those who developed a MI compared with those who did not. Although IL-6 is associated with CRP, IL-6 is still an independent risk factor.
[15]
ICAM-1 Acute MI After a MI, ICAM-1 is significantly increased for at least 5 days. There is also a small rise in ICAM-1 in the coronary sinus, but not systemic circulation after angioplasty.
[17]
Acute MI/angioplasty Early in an acute MI, ICAM-1 is elevated and remains elevated in patients who developed early restenosis.
[18]
Children ICAM-1 is positively correlated with apoB B/A-I and risk factors for atherosclerosis.
[19]
Peripheral vascular disease ICAM-1 is associated with subsequent cardiac events, although this was not independent.
[20]
Healthy men Increased ICAM-1 predicts future myocardial infarctions.
[1]
CRP=C-reactive protein; ICAM-1=intracellular adhesion molecule-1; MI=myocardial infarction.
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can be used as markers of increased risk of future cardiac events. In acute coronary syndromes, elevations in these biomarkers are associated with the extent of myocardial cell damage. Newer studies, such as the one of O'Malley and colleagues add to our existing knowledge by determining the early timing and prognostic significance or lack thereof for CRP, IL-6 and ICAM-1 in acute coronary syndromes. Placing these intriguing data in perspective is difficult. As illustrated in the accompanying table, there is now a growing body of evidence supporting the presence of clinical markers of inflammation in a variety of acute and chronic coronary syndromes.
Even so, while we should be stimulated by the translation of these basic concepts into a clinical setting, we need to be mindful of the caveats. Studies such as this represent a laudable attempt to bridge the gap between basic science and clinical medicine but basically demonstrates as association. Associations may imply incrimination but fall far short of a cause-and-effect relationship and their implications for treatment. Moreover, elevations in serum markers are probably not surrogate end-points for treatment or clinical trials, and in any event others have comprehensively addressed the limitations of using surrogates as end-points for therapeutic interventions [21] . Nonetheless, the study by O'Malley et al. provides another indicator towards the direction in which we are travelling. Elevated systemic markers of inflammation in both acute and chronic manifestations of atherosclerosis, help us understand the underlying pathogenesis of these diseases and tend to confirm the role of inflammation in both chronic coronary artery disease and the acute coronary syndrome. Traditional theories of the pathogenesis and manifestations of atherosclerosis have undergone dramatic change during the last decade, and a sense of expectation and indeed excitement can only characterize the near future. Does inflammation play a role in atherosclerosis? It would certainly appear to be the case, but the panacea of antibiotics as a primary therapy for atherosclerosis is certainly not in the present and may not be in the future.
The route through the maze of atherosclerosis will lie in basic research translated into smaller hypothesis-driven studies, leading to those involving larger populations such as the study by O [1] . Several reports have demonstrated that despite a higher incidence of in-hospital complications and mortality, as compared with younger patients, cardiac surgery can be performed in the elderly with acceptable risk, resulting in improved quality of life [2] [3] [4] [5] [6] . However, these patients usually have more advanced and diffuse cardiovascular disease with higher co-morbidity, such as cerebrovascular and peripheral vascular disease, diabetes, pulmonary and/or renal dysfunction, carrying a greater risk of significant disabling complications and prolonged hospital stay. Furthermore, biological ageing is quite heterogeneous and precise algorithms should be replaced by integrative individualized management. The most difficult aspects of decision making are choosing the appropriate timing of surgery and the necessity of whether or not to perform combined valve and coronary procedures.
The report of Kolh and associates in this issue [7] addresses the early and late outcome of 182 octogenarians submitted to cardiac surgery, with a mean follow-up of more than 3 years, providing 459 patient years of observation. Among the 182 octogenarians, 24 (13%) died during the hospital stay and 107 (59%) had one or more complications. Most patients recovered. Reoperation was required in 14 patients (8%). Only five patients (3%) developed stroke: ascending aortic atheromatous disease, as assessed during operation, was the single predictor of stroke. Urgent operation was performed in 33 patients (18%). Forty-five patients (25%) were in functional class III and 46 (also 25%) were in class IV. Independent predictors of early in-hospital mortality were duration of extracorporeal circulation, urgent operation and functional class IV. Independent predictors of late mortality were urgent surgery again and pre-operative myocardial infarction. In this retrospective study, few patients underwent mitral valve repair or replacement. Seventy patients were submitted to isolated aortic valve replacement, 70 to isolated coronary artery bypass grafting and 30 had combined aortic valve replacement and coronary artery bypass grafting. Hospital mortality was relatively low in the patients submitted to a single operation (8·5% and 10%, respectively) but was much higher among patients with combined valve and coronary surgery (26·5%).
Although the results of this and other studies clearly indicate that surgery should not be denied to octogenarians on the basis of age only, several improvements could potentially reduce the short-and the long-term risks. Urgent surgery, a too long duration of extracorporeal circulation and delayed surgery until the patient is in functional class IV should be avoided as much as possible.
Aortic valve replacement
Among the 100 patients submitted to aortic valve replacement in the series of Kolh et al. [7] , 31 were in class IV and 21 had an urgent procedure. The patients presented with a mean of 2·3 of the four classical Editorials 1159
